跳至主要内容
临床试验/CTRI/2022/01/039602
CTRI/2022/01/039602尚未招募2 期

To Evaluate the therapeutic efficacy of Habb-e-Asgand in the management of Waja-ul-Mafasil(Rheumatoid Arthritis).A Randomized, Single blind, Standard Controlled Trial.

Central Council for Research in Unani Medicine0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
尚未招募

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1 Clinically diagnosed /or serological evidence of Rheumatoid arthritis(Waja-ul-Mafasil). 2 Patients who have agreed to sign the informed consent, follow the protocol and willing to participate in clinical trial voluntarily.3 Mild to Moderate cases of Rheumatoid Arthritis.4 Have a diagnosis of Rheumatoid Arthritis (RA) as defined by American College of Rheumatology/ European League Against Rheumatism (ACR/EULAR)2010 Criteria for the Classification of RA.

排除标准

  • 1. Uncontrolled Diabetes mellitus.
  • 2. Hepatic or Renal insufficiency.
  • 3. Other type of arthritis.
  • 4. Pregnancy and lactation.
  • 5. Any joint surgery in the previous 6 months
  • 6. Patients with cardiovascular diseases.
  • 7. Patients who refuse to give the written
  • consent for the study.
  • 8. Severe cases of Rheumatoid Arthritis

研究者

相似试验